Introduction {#section6-0269881118783299}
============

The acute effects of cannabis and cocaine on cognitive functions of recreational drug users have been repeatedly assessed in placebo-controlled experimental studies. These studies have shown that a single dose of delta-9-tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis, impairs performance in laboratory tasks measuring executive function, impulse control, psychomotor performance ([@bibr42-0269881118783299]; [@bibr59-0269881118783299]), attention ([@bibr42-0269881118783299]; [@bibr52-0269881118783299]) and memory (see review [@bibr17-0269881118783299]; [@bibr43-0269881118783299]; [@bibr52-0269881118783299]). Single doses of cocaine have been shown to impair impulse control, while improving psychomotor function ([@bibr42-0269881118783299]; [@bibr59-0269881118783299]) and attention ([@bibr42-0269881118783299]). Acute effects of cocaine on memory, however, have not been studied extensively ([@bibr49-0269881118783299]). Studies in dependent cocaine users ([@bibr16-0269881118783299]; [@bibr23-0269881118783299]) and recreational users ([@bibr22-0269881118783299]) revealed no influence of single doses of cocaine on memory.

Psychostimulants such as cocaine have been used as performance enhancers throughout history ([@bibr62-0269881118783299]). At present, increasing numbers of adults, particularly college students, are misusing psychostimulants primarily for cognitive enhancement ([@bibr30-0269881118783299]). Animal studies have demonstrated that single doses of psychostimulants such as methylphenidate ([@bibr2-0269881118783299]; [@bibr3-0269881118783299]) and cocaine ([@bibr50-0269881118783299]) enhance learning and memory. Human drug studies on memory enhancement following psychostimulant administration have mostly focused on tasks measuring retrospective memory, i.e. recalling past events or knowledge ([@bibr28-0269881118783299]; [@bibr32-0269881118783299]). Stimulant effects on prospective memory, however, have hardly been studied so far. Prospective memory involves the capacity and integrity of memory to encode, retrain and recollect future intentions and actions such as remembering to call a friend, take medication or go to a meeting, and differs from retrospective memory in that it involves self-initiated retrieval, sometimes cued by an event or time ([@bibr7-0269881118783299]; [@bibr8-0269881118783299]; [@bibr25-0269881118783299]; [@bibr31-0269881118783299]). Chronic use of methamphetamine ([@bibr10-0269881118783299]), cocaine and MDMA ([@bibr13-0269881118783299]; [@bibr14-0269881118783299]; [@bibr20-0269881118783299]) as well as single dose administrations of MDMA ([@bibr39-0269881118783299]) have been associated with impairments of prospective memory. Likewise, sedative drugs such as alcohol and cannabis have also been associated with prospective memory deficits both after acute dose administrations ([@bibr33-0269881118783299]; [@bibr37-0269881118783299]; [@bibr52-0269881118783299]) as well as after chronic use ([@bibr4-0269881118783299]; [@bibr19-0269881118783299]; [@bibr21-0269881118783299]; [@bibr27-0269881118783299]).

Drug effects on prospective memory may represent specific alterations in memory processing or may result from more general effects on cognition that spread across multiple domains ([@bibr10-0269881118783299]). For example, drug-induced reductions or increments in arousal and attention may indirectly lead to a decline or boost of memory performance, as high levels of arousal and attention have been associated with enhanced prospective memory performance ([@bibr29-0269881118783299]; [@bibr44-0269881118783299]). Impairments in prospective memory, as observed after acute doses of cannabis ([@bibr52-0269881118783299]) and alcohol ([@bibr33-0269881118783299]; [@bibr37-0269881118783299]), may thus result from decrements in attention and arousal, rather than from a decrement of memory processing per se. Likewise, memory enhancement, as observed for stimulants ([@bibr28-0269881118783299]; [@bibr32-0269881118783299]), may reflect an increase in concentration and arousal rather than an improvement in memory processes per se.

The current study was designed to assess the acute influence of single dose of cocaine and of cannabis on prospective memory and to assess whether drug-induced changes in prospective memory are associated with drug-induced changes in attention and arousal. In order to test these aims, a double-blind, placebo-controlled, cross-over study was designed. Drug effects on attention and arousal were assessed using a divided attention task and subjective measure of arousal. It was expected that after cannabis administration prospective memory would be impaired, while cocaine administration was expected to improve prospective memory performance.

Methods {#section7-0269881118783299}
=======

Design {#section8-0269881118783299}
------

The study design was double-blind, placebo-controlled, within-subject with three treatment conditions consisting of placebo, 450 µg/kg THC and 300 mg cocaine hydrochloride (HCl). The cannabis dose was divided over two doses of 300 and 150 µg/kg THC bodyweight (booster dose) with an interval of approximately 1.5 h, in order to maintain THC concentrations throughout a three-hour time window. For a time line of the study design, see [Figure 1](#fig1-0269881118783299){ref-type="fig"}. Cannabis was administered through a vaporiser (Volcano) obtained from Storz and Bickel GmbH and Co (Tuttlingen, Germany) and was used according to the manual provided by the producer. Cannabis vaporization is a technique by which cannabis plant material is heated to a temperature where active cannabinoid vapours form. This is considered a safe and effective way of administering cannabis ([@bibr18-0269881118783299]). The vapours are then collected in a detachable plastic balloon of 55 cm length. The balloon can be removed from the device and fitted with a mouthpiece for inhalation. Participants were instructed to empty the balloon in 4--5 breaths. After each inhalation, participants had to hold their breath for 10 seconds before exhaling. The vapour was prepared from batches containing 11% THC, a standard potency for cannabis sold at Dutch pharmacies for medicinal use. As placebo, a herbal plant mixture ('Knaster') was used. The density of the vapour captured in the balloon did not noticeably differ between THC and placebo. Cocaine HCl or placebo was administered in an opaque white capsule. Treatments were administered using a double dummy technique. Conditions were separated by a minimum wash-out period of seven days to avoid cross-condition contamination. The order of conditions was balanced over participants and sessions.

![Timeline of the course of a testing day. The red arrow indicates the moment of cocaine (or placebo) capsule administration and the green arrows represent the delta-9-tetrahydrocannabinol (THC) (or placebo) vapour administration. DAT: divided attention task; PMT: prospective memory task; POMS: Profile of Mood States.](10.1177_0269881118783299-fig1){#fig1-0269881118783299}

Participants {#section9-0269881118783299}
------------

The present study was part of a larger trial on the association between drug use and impulse control, of which a large part of the data has been published elsewhere ([@bibr41-0269881118783299]; [@bibr59-0269881118783299]; [@bibr57-0269881118783299]). Initially, 16 healthy poly-drug users from the large trial were included in this part of the study. However, due to non-compliance with the task instructions, one participant was removed from the final sample that entered the data analysis. Participants (14 males; one female) were aged 22.8 years (standard deviation (SD)=2.6) on average and with a mean weight of 67.7 kg (SD=10.8). The details on their cannabis and cocaine use are depicted in [Table 1](#table1-0269881118783299){ref-type="table"}. Cannabis use history across participants was somewhat equally divided, ranging from use on 1--24 (*n*=4); 25--49 (*n*=3); 50--74 (*n*=3) and 75--100 (*n*=5) occasions during the past three months (based on cannabis use history groups from [@bibr42-0269881118783299]). Participants also reported a drug use history of ecstasy (60%), amphetamines (33%), mushrooms (47%), LSD (20%) and other drugs (20%).

###### 

Mean (±standard deviation (SD)) drug use in the past three months and total years of use.

![](10.1177_0269881118783299-table1)

                 Use previous three months   Years of use                                               
  -------------- --------------------------- -------------- --------------- ---- --- ---- ------------- -----------------------------------------------------------
  **Cannabis**   10                          100            50.13 (31.49)   15   3   14   6.5 (2.98)    14^[a](#table-fn1-0269881118783299){ref-type="table-fn"}^
  **Cocaine**    0                           10             3.80 (0.83)     15   1   6    3.62 (1.94)   13^[a](#table-fn1-0269881118783299){ref-type="table-fn"}^

Missing data.

Participants were recruited through advertisements in local newspapers and by word of mouth. Before inclusion, participants were examined by a medical supervisor, who checked for general health and took blood samples and a urine sample for standard chemistry and haematology. Inclusion criteria were: written informed consent; age 18--40 years; regular cannabis and cocaine use defined as two times per week or more for cannabis and at least five times in the past year for cocaine; free from psychotropic medication; good physical health as assessed by a medical doctor; normal weight as determined by body mass index (BMI) 18--28. Exclusion criteria were: addiction to cocaine according to the Diagnostic and Statistical Manual, version 5 (DSM-IV) criteria; presence or history of psychiatric or neurological disorder as assessed during a clinical interview; pregnancy or lactating; cardiovascular abnormalities; excessive drinking or smoking, and hypertension.

Procedures {#section10-0269881118783299}
----------

Participants were familiarised with all tests and procedures during a training session, before the start of the actual test days. They were asked to refrain from all drugs of abuse (except cannabis) at least one week before the study start until the last test day. They were asked not to use any caffeinated or alcoholic beverages 24 h before testing and to get a normal night of sleep. All participants indicated that they had not smoked cannabis in the morning prior to testing. At 09:00, prior to the experimental sessions they were screened for presence of drugs of abuse in urine (THC/opiates/cocaine/amphetamines/methamphetamines) and they had to pass a breathalyser ethanol test. Women were given a pregnancy test. When tests were negative (except for cannabis), participants filled out a questionnaire to assess sleep complaints, and had a light standard breakfast. After breakfast at 10:00, participants were administered a capsule containing either 300 mg cocaine HCl or placebo orally. Forty-five minutes after capsule administration, participants inhaled 300 µg/kg bodyweight cannabis or placebo. In between treatments, participants were allowed to read a book or watch television. After conducting laboratory tests, assessing impulsivity, psychomotor performance (results published in [@bibr59-0269881118783299]) and divided attention (DAT at 11:45) participants received a second 'booster dose' of cannabis or placebo (150 µg/kg bodyweight at 12:30) and they proceeded with the second part of the study. After the 'booster dose', a visual analogue scale (VAS) assessing subjective high and the Profile of Mood States (POMS) was administered, followed by the prospective memory task. Blood samples were taken three times a day, at baseline, just before the prospective memory task (12:30) and at the end of the test day (13:30). Relative to cocaine and cannabis administration, the second blood sample was collected 2.5 h post-cocaine administration and immediately after the second cannabis vapour inhalation; the third blood sample was collected 3.5 h post-cocaine administration and one hour after the second cannabis administration. A schematic representation of the time course of a testing day is represented in [Figure 1](#fig1-0269881118783299){ref-type="fig"}.

The study was conducted according to the code of ethics on human experimentation established by the Declaration of Helsinki (1964) and subsequent amendments, and it was approved by the Medical Ethics Committee of the Academic Hospital of Maastricht and Maastricht University. A permit for obtaining, storing and administering cocaine and cannabis was obtained from the Dutch drug enforcement administration. Participants signed an informed consent and were paid upon completion of the testing periods for their participation.

Performance tests {#section11-0269881118783299}
-----------------

### Prospective memory task (PMT) {#section12-0269881118783299}

The event-based PMT assessed participants' ability to remember and execute upon the occurrence of a specific future event. Participants were engaged in a foreground task that consisted of pushing as quickly as possible one of two buttons in response to stimuli (letter A or B) presented on a screen. In total, 100 letters were presented with both letters presented equally often. Participants were also given a second prospective task, i.e. to withhold their response during trials that were part of a dynamic memory set. A trial counter that was always present in the left top corner of the screen informed the participants about the number of the trial. In addition, participants were presented at irregular times with a future trial number in the right top corner of the display. Participants were instructed to remember this future trial number and withhold from responding to the foreground task during the actual occurrence of the future trial. The memory set of subjects was dynamic and contained up to three future trial numbers. A trial number in the memory set was replaced by a novel future trial number whenever the actual trial number matched a future trial number in the set. Trials during which participants were expected to respond were classified as Go trials. Trials during which subjects were instructed to withhold a response were classified as No-Go trials (prospective memory trials). The time between the presentation of a future trial number and the actual occurrence of the trial called 'the memory delay'; varied between one, two and three minutes, equally divided over all No-Go trials. Each trial lasted for 12 s. However, the central letters disappeared upon a button press. Presentations of future trial numbers lasted four seconds. In total, the PMT consisted of 68 Go trials and 24 No-Go trials. At the beginning and the end of the task, a total of eight trials were presented during which the memory set was empty. The percentage of correct inhibitions in No-Go trials was the primary performance parameter. Number of correct responses and corresponding reaction time during Go trials were the secondary performance parameters. The PMT lasted for 20 min. Three parallel versions of the PMT were developed for administration during the test sessions to avoid learning effects. The PMT was proven to be sensitive to the acute effects of MDMA ([@bibr39-0269881118783299]; [@bibr58-0269881118783299]).

### Divided attention task (DAT) {#section13-0269881118783299}

The DAT assessed participants' ability to divide attention between two tasks performed simultaneously ([@bibr34-0269881118783299]). Participants were engaged in a tracking task that measured the ability to control a displayed error signal ([@bibr24-0269881118783299]), which was displayed as a horizontal deviation of a cursor from the midpoint on a horizontal, linear scale. Simultaneously, participants had to monitor 24 single digits which were presented in the corners of the computer screen. Participants were instructed to react to the target number '2' by removing their foot as fast as possible form a pedal switch. Mean absolute tracking error (in mm) and percentage of correct detections (hits %) of the target number were the performance measures.

Subjective measures {#section14-0269881118783299}
-------------------

### Arousal {#section15-0269881118783299}

Arousal level was measured by the POMS questionnaire. Participants had to express their level of mood on a five-point Likert scale, with zero being 'not at all' to four 'extremely'. The level of arousal was determined by using a composite score of four levels of mood; anxiety (nine items), confusion (seven items), fatigue (seven items) and vigour (eight items); accordingly arousal level was calculated through combining the four levels of mood ((anxiety+vigour)−(fatigue+confusion)) ([@bibr5-0269881118783299]).

### VAS {#section16-0269881118783299}

Participants had to assess their levels of subjective high via a VAS (10 cm); with zero indicating 'not high at all' and 10 indicating 'extremely high'.

Pharmacokinetic assessments {#section17-0269881118783299}
---------------------------

Blood samples to determine cannabis and cocaine concentrations were taken at baseline, 2.5 h and 3.5 h after cocaine or placebo capsule administration. Blood samples were centrifuged at 3500 rpm and resulting serum and plasma were frozen at −20°C until analysis for pharmacokinetic assessments. The determination of THC and its metabolites, 11-hydroxy-THC (THC-OH) and 11-nor-9-carboxy-THC (THC-COOH), was performed in serum; determination of cocaine, and its metabolites benzoylecgonine (BZE) and ecgonine methyl ester (EME) was performed in plasma. Determination took place in a specialized forensic-toxicological laboratory using validated procedures ([@bibr54-0269881118783299]; [@bibr53-0269881118783299]).

Statistical analysis {#section18-0269881118783299}
--------------------

PMT and DAT data, subjective measures of arousal and subjective high, and blood concentrations were checked for normality, using Kolmogorov-Smirnov tests of normality. Normality tests per treatment condition showed that reaction time on Go trials, percentage correct detections (hits %), VAS subjective high and baseline blood levels of THC and its metabolites were not normally distributed. In addition, normality tests across all conditions showed that percentage correct in Go trials, percentage correct in No-Go trials and percentage correct detections (hits %) were not normally distributed.

Normally distributed data were analysed by means of a general linear model (GLM) repeated measures analysis of variance (ANOVA) version SPSS 24.0 with treatment (three levels, i.e. placebo, cocaine and cannabis) as the within-subjects (WS) factor. In case of main effects, subsequent treatment contrasts were performed. In case of a main treatment effect, subsequent polynomial contrasts were added as a linear trend analysis across all treatments. Non-normal distributed data was analysed with a non-parametric Friedman test to test the main effects of treatment, with subsequent Wilcoxon signed-rank test for treatment contrasts, in case of main effects.

A series of correlation analyses was conducted to assess relationships between prospective memory and arousal levels, prospective memory and attention performance (hits % and tracking error); and between arousal levels and attention performance (hits % and tracking error) over all conditions. In addition, correlation analyses were conducted to assess relationship between cannabis and cocaine blood concentrations respectively, and drug-placebo differences of prospective memory failures. The first correlation analysis provides information about the association between prospective memory and arousal and attention, and the association between arousal and attention. The latter provides information on the drug concentration in blood and the acute effects of both drugs on prospective memory performance. Correlation analyses of normally distributed data was analysed by Pearson correlation, while non-normal data distribution was analysed using Kendall's Tau-b correlation.

The alpha criterion level of statistical significance for all analyses was set at *p*=0.05. Partial eta squared (partial *ƞ^2^*) is reported in case of significant effects to demonstrate the effect's magnitude, where 0.01 is defined as small, 0.06 as moderate and 0.14 as large. Partial eta squared is based on Cohen's *f* which defines small, medium and large as respectively 0.10, 0.25 and 0.50 which corresponds to *ƞ^2^* of 0.0099, 0.0588 and 0.1379 ([@bibr45-0269881118783299]).

Results {#section19-0269881118783299}
=======

Missing data {#section20-0269881118783299}
------------

Due to technical issues, computer responses were not registered, resulting in missing data for the DAT in the placebo condition for one person and cocaine condition for another person. Some of the blood samples were missing due to inability to draw blood (see [Table 2](#table2-0269881118783299){ref-type="table"}).

###### 

Mean (±standard deviation (SD)) concentrations of delta-9-tetrahydrocannabinol (THC) (ng/mL), cocaine (mg/L) and their main metabolites.

![](10.1177_0269881118783299-table2)

  Condition      Concentration                                               *n*                                                         Baseline                                                    *n*                                                         Before PMT                                                  *n*                                                         End test day
  -------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- --------------
  **Placebo**    THC                                                         13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   3.4 (7.6)                                                   13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   2.3 (2.3)                                                   13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   2.1 (3.0)
  THC-OH         13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   1.4 (2.7)                                                   13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   0.9 (1.0)                                                   13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   0.9 (1.2)                                                   
  THC-COOH       13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   42.7 (58.4)                                                 13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   33.8 (43.7)                                                 13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   36.3 (52.3)                                                 
  **Cannabis**   THC                                                         11^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   3.3 (5.9)                                                   11^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   35.2 (21.3)                                                 11^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   8.3 (4.5)
  THC-OH         11^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   1.1 (1.6)                                                   11^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   5.8 (2.7)                                                   11^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   3.3 (1.4)                                                   
  THC-COOH       11^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   40.6 (51.6)                                                 11^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   50.7 (38.9)                                                 11^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   41.6 (33.4)                                                 
  **Cocaine**    THC                                                         13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   2.3 (3.3)                                                   12^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   3.1 (4.3)                                                   12^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   2.2 (3.1)
  THC-OH         13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   1.1 (1.6)                                                   12^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   1.2 (1.9)                                                   12^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   1.0 (1.5)                                                   
  THC-COOH       13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   31.2 (39.4)                                                 12^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   34.7 (49.6)                                                 12^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   30.53 (45.8)                                                
  Cocaine        13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   0.0 (0.0)                                                   13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   0.4 (0.2)                                                   13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   0.1 (0.1)                                                   
  BZE            13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   0.0 (0.0)                                                   13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   1.0 (0.3)                                                   13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   1.2 (0.4)                                                   
  EME            13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   0.0 (0.0)                                                   13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   0.3 (0.1)                                                   13^[a](#table-fn3-0269881118783299){ref-type="table-fn"}^   0.2 (0.1)                                                   

BZE: benzoylecgonine; EME: ecgonine methyl ester; PMT: prospective memory task.

Missing samples.

PMT {#section21-0269881118783299}
---

GLM repeated measures ANOVA revealed a main effect of treatment on percentage correct inhibitions of No-Go's (*F~2,28~*=9.47, *p*\<0.01, *ƞ~p~^2^*=0.40). Subsequent treatment contrasts revealed that percentage of correct inhibitions was higher following cocaine as compared with placebo (*p*=0.03) and as compared with cannabis (*p*\<0.01). Treatment contrast between cannabis and placebo was not significant. However polynomial contrasts revealed a linear trend across all treatments (*F~1,14~*=31.83, *p*\<0.01), indicating that correct inhibitions during No-Go trials were highest after cocaine, intermediate after placebo and lowest following cannabis treatment. Mean (M) (±standard error (SE)) performance scores of the percentage correct inhibitions are shown in [Figure 2(a)](#fig2-0269881118783299){ref-type="fig"}.

![Mean (±standard error (SE)) (a) percentage correct inhibitions No-Go trials, (b) percentage correct detections, (c) tracking error and (d) arousal rating after cocaine and cannabis administration and placebo. \*significant differences between conditions with *p*\<0.05.](10.1177_0269881118783299-fig2){#fig2-0269881118783299}

Friedman test revealed treatment effects on reaction time (*x*²(2)=9.73, *p\<*0.01) and on percentage correct in the Go trials (*x*²(2)=10.32, *p*=0.01). Subsequent treatment contrasts revealed an impairing effect of cannabis on reaction time (*Z*=−2.39, *p*=0.02) and percentage correct in the Go trials (*Z*=−2.29, *p*=0.02) compared with placebo; and a significant impairing effect of cannabis as compared with cocaine on reaction time (*Z*=−2.33, *p*=0.02) and percentage correct Go trials (*Z*=−3.02, *p*\<0.01). There was no significant difference comparing cocaine and placebo treatment on reaction time and percentage correct in Go trials. During cocaine treatment reaction time was fastest (M=1065.8, SE=106.02), placebo in between (M=1179.3, SE=72.14) and during cannabis responses were the slowest (M=1297.1, SE=86.61). Percentage correct in the Go trials was highest after cocaine (M=94.8, SE=1.41), intermediate after placebo (M=90.3, SE=2.87) and lowest after cannabis administration (M=84.2, SE=3.84).

DAT {#section22-0269881118783299}
---

Friedman test revealed treatment effects of percentage correct detections (hits %) (*x*²(2)=6.68, *p*=0.04), subsequent treatment contrasts revealed that percentage of hits was higher during cocaine as compared with cannabis (*Z*=−2.04, *p*=0.04). Treatment contrasts comparing placebo with cocaine and placebo with cannabis were not significant. GLM repeated measures ANOVA revealed a main effect of treatment on tracking error (*F~2,24~*=4.08, *p=*0.03, *ƞ~p~^2^*=0.25), with subsequent treatment contrasts revealing a reduction in tracking error during cocaine as compared with cannabis (*p*=0.01). Again, treatment contrasts comparing placebo with cocaine and placebo with cannabis were not significant. Polynomial contrasts revealed a linear trend across all treatments (*F~1,12~*=10.29, *p=*0.01), indicating that tracking error was lowest after cocaine, intermediate after placebo and highest following cannabis treatment. Mean (±SE) performance scores for the divided attention task is shown in [Figure 2(b)](#fig2-0269881118783299){ref-type="fig"} and ([c](#fig2-0269881118783299){ref-type="fig"}).

Arousal {#section23-0269881118783299}
-------

Mean (±SE) arousal levels in every treatment condition are shown in [Figure 2(d)](#fig2-0269881118783299){ref-type="fig"}. GLM repeated measures ANOVA revealed a main effect of treatment on arousal levels (*F~2,28~*=9.71, *p*\<0.00, *ƞ~p~^2^*=0.41), subsequent treatment contrasts revealed higher arousal levels following cocaine administration as compared with placebo (*p*=0.01) and as compared with cannabis (*p\<*0.01). Treatment contrast between cannabis and placebo was not significant. Polynomial contrasts revealed a linear trend across all treatments (*F~1,14~*=13.84, *p*\<0.01), indicating that arousal levels were highest after cocaine, intermediate after placebo and lowest following cannabis treatment.

Subjective high {#section24-0269881118783299}
---------------

Friedman test revealed treatment effects of subjective high (*x*²(2)=15.17, *p*\<0.01), subsequent treatment contrasts revealed that both cocaine and cannabis increased subjective high relative to placebo (*Z*=−2.20, *p*=0.03; *Z*=−3.19, *p*\<0.01). Mean subjective high was higher during cannabis treatment as compared with cocaine (*Z*=−2.35, *p*=0.02). Mean levels of subjective high were highest after cannabis administration (M=5.7, SE=0.70), intermediate following cocaine (M=3.3, SE=0.77) and lowest after placebo (M=1.3, SE=0.26). Results show that both treatments were significantly intoxicated compared with placebo.

Blood concentrations {#section25-0269881118783299}
--------------------

Blood concentrations during cocaine, cannabis and placebo treatments are shown in [Table 2](#table2-0269881118783299){ref-type="table"}. The cannabinoid analyses revealed the presence of THC and its metabolites in all conditions at baseline which are a consequence of repeated cannabis use (see [Table 1](#table1-0269881118783299){ref-type="table"}, [@bibr53-0269881118783299]). Friedman test revealed no significant difference in levels of THC (*x*²(2)=2.25, *p*=0.33), THC-OH (*x*²(2)=0.48, *p*=0.79) and THC-COOH (*x*²(2)=1.11, *p*=0.58) across all three conditions, indicating level of THC and its metabolites are similar for all three conditions at baseline.

Correlations {#section26-0269881118783299}
------------

Kendall's Tau-b correlation analyses revealed significant but low associations between prospective memory and arousal (*τ*~b~=0.33; *p*=0.01), tracking error (*τ*~b~=−0.32; *p*=0.04), and correct detections (*τ*~b~=0.26; *p*=0.02); indicating that better prospective memory performance was somewhat associated with higher arousal levels and enhanced attention as shown in [Figure 3](#fig3-0269881118783299){ref-type="fig"}. In the latter case, the correlation seemed to be driven by three outlying data points (see [Figure 3(c)](#fig3-0269881118783299){ref-type="fig"}), which seemed like the results of one participant, however these data points represent three different participants. Pearson correlations between attention performance and arousal only revealed a low association between tracking error and arousal (*r~43~*=−0.34; *p*=0.03), indicating that higher levels of arousal are only slightly associated with the primary task variable (tracking) and not associated with the secondary task variable (correct detections) of attention.

![Scatterplots of percentage correct inhibitions No-Go trials as a function of (a) arousal, (b) tracking error and (c) correct detections. Correlations (*τ*~b~) significant with *p*\<0.05. DAT: divided attention task; PMT: prospective memory task.](10.1177_0269881118783299-fig3){#fig3-0269881118783299}

Cocaine and THC concentrations in serum were not correlated to performance in the No-Go trials of the prospective memory task, indicating a homogenous participant sample.

Discussion {#section27-0269881118783299}
==========

The current study aimed to assess the influence of single-dose administration of cocaine and cannabis on prospective memory and to determine whether cocaine and cannabis induced changes in prospective memory depend on changes in attention and arousal. Cocaine administration enhanced prospective memory performance relative to placebo and cannabis. Prospective memory performance was lowest after cannabis, in between after placebo and highest after cocaine administration, evinced by a linear trend across treatment conditions. Cocaine also improved performance on the primary (tracking) and secondary (correct detections) task of the divided attention test, relative to cannabis. Tracking performance was lowest in the cannabis condition but increased following placebo and cocaine. After cocaine administration, subjective arousal levels were increased as compared with placebo and cannabis. Once again arousal levels were lowest in the cannabis condition and increased after placebo and cocaine. Only a small part of the enhancing effects of cocaine on prospective memory can be explained by underlying changes in arousal and attention.

The present study was the first to demonstrate that acute administrations of cocaine can enhance prospective memory. The present study however showed that prospective memory performance was only poorly associated with divided attention performance and arousal. Correlations between prospective memory performance and measures of attention and arousal ranged between *τ*~b~ −0.32 and 0.33. This indicates that these constructs only explained a very small portion of the variance observed in prospective memory performance. Memory enhancement, as observed after cocaine in the present study therefore, is more likely to have resulted from direct improvement of the prospective memory circuits rather than from a general increase in attention. This finding seems in line with animal studies showing that exposure to cocaine may directly enhance hippocampal function and memory. For example, it has been demonstrated that cocaine induces a rapid increase in the formation and accumulation of new dendritic spines in the frontal cortex, and that such changes in structural plasticity correlate with an increased ability to learn new stimulus-related information ([@bibr35-0269881118783299]). Likewise, [@bibr36-0269881118783299] demonstrated that cocaine facilitates the learning of new tasks in rats even though retrieval of information learned prior to cocaine administration was impaired. Such improvement in memory and learning, however, does not automatically imply that cocaine should be used as a preferred cognition enhancer. Indeed, many animal studies have pointed out that the precognitive effects of cocaine may play a role in drug seeking behaviour by strengthening the formation of maladaptive associations between drug use, context and cues ([@bibr26-0269881118783299]). Yet, the present data does suggest that cocaine-induced cognition, and therefore enhancement or changes in synaptic plasticity, may very well exceed the context of drug reinforcement learning.

Cocaine-induced enhancement of prospective memory might generalise to other domains of memory as well. For example, retrospective and prospective memory processes do not operate completely independent from each other which would allow transfer of procedural deficits in retrospective to prospective memory ([@bibr9-0269881118783299]; [@bibr61-0269881118783299]). Alternatively, individuals with a deficit in prospective memory do often display normal operation of retrospective memory ([@bibr56-0269881118783299]). This suggest that while both memory processes overlap, they are not necessarily interchangeable ([@bibr12-0269881118783299]; [@bibr61-0269881118783299]). Transferability of drug effects between different memory processes, therefore, may depend on whether a drug acts on a memory mode that is being shared by memory circuits. For example, it has been pointed out that performance on prospective and retrospective memory tasks in part relies on a similar retrieval mode that is located in BA10 ([@bibr55-0269881118783299]). We do not know whether cocaine-enhanced encoding, retrieval or storage of information in our participants. Yet, in the case that a common retrieval process was positively affected by cocaine, we would expect memory enhancement to appear both in retrospective as well as PMTs. What is evident is that prospective memory performance heavily relies on working memory processes as the task is very dynamic and requires continuous updating and retrieval of novel information. Working memory and prospective memory processes are not based on the same memory system, but prospective memory is highly demanding of working memory resources ([@bibr1-0269881118783299]). Several studies have shown that prospective memory is related to individual working memory capacity ([@bibr6-0269881118783299]; [@bibr47-0269881118783299]; [@bibr60-0269881118783299]). As cocaine enhanced prospective memory, it can be expected that cocaine enhances working memory as well.

Memory enhancement has also been demonstrated for stimulant drugs with similar mechanisms of action as cocaine. Adults with attention deficit hyperactivity disorser treated with methylphenidate showed improved memory functions when compared with non-medicated patients across a range of memory domains, including prospective memory ([@bibr11-0269881118783299]). Similar effects have been reported in healthy volunteers. A review of methylphenidate studies in healthy volunteers ([@bibr28-0269881118783299]) showed that single doses of methylphenidate enhance working memory in 65% of the included studies and, to a lesser extent, verbal learning and memory in 31% of the studies. Cocaine and methylphenidate are also being misused by healthy college students to enhance their study performances although the effectiveness of this approach is largely unknown ([@bibr30-0269881118783299]; [@bibr51-0269881118783299]). Cocaine and methylphenidate share the same dopamine as well as noradrenaline enhancing effects, by blocking dopamine and noradrenaline transporters ([@bibr15-0269881118783299]; [@bibr46-0269881118783299]). Additionally, cocaine also inhibits the serotonin transporter. Similarities in their pharmacological profiles seem to indicate that the enhancement of dopamine and noradrenaline levels during cocaine treatment may underlie the neurobiological changes in memory.

The influence of cannabis on prospective memory and attentional performance was much as expected. Previous studies already demonstrated that single doses of THC can significantly impair prospective memory ([@bibr52-0269881118783299]) and attention ([@bibr42-0269881118783299]). In the present study, performances during cannabis and placebo did not significantly differ from each other when statistically compared with cannabis-placebo contrasts. However, mean performance during cannabis was always worse as compared with placebo, and the trend showing an increase in performance from cannabis, placebo to cocaine administration was highly significant. In addition, THC blood levels after cannabis administration in the present study (M=35.2, SD=21.3) are about the same as blood levels of [@bibr52-0269881118783299] (M=30.7, SD=27.4), indicating adequate blood levels were reached after cannabis administration. In the present study, the cannabis condition primarily served as an active control for the placebo condition to widen the coverage of the memory, arousal and attention performance ranging from poor to normal enhancement. As such, the inclusion of cannabis treatment increased the overall reliability of correlational analyses between measures of prospective memory and measures of attention and arousal.

Repeated cannabis use leads to residual concentrations of THC and its metabolites ([@bibr53-0269881118783299]) as observed for baseline analyses in the present study. However, we do not expect that these baseline levels would interfere with test performances as these concentrations did not differ across treatment conditions. In addition, concentrations as determined here were found not to be relevant for the observed effects ([@bibr38-0269881118783299]; [@bibr42-0269881118783299]; [@bibr40-0269881118783299]). However, chronic use of cannabis can lead to memory impairments which can last for weeks, months or even years ([@bibr48-0269881118783299]), so stimulants like cocaine might reverse these deficits if present.

The present data revealed that the prospective-memory-enhancing effects of cocaine can only be explained partly by enhanced attention and arousal levels. It might be argued that a low association between prospective memory and attention might have resulted from a lack of a very strong drug effect on attentional performance. Indeed, performance on the DAT primarily differed between drug conditions and not between drug and placebo treatment. Perhaps drug effects on attention would have appeared more prominent if the sample size had been bigger. However, the cocaine effect on prospective memory and arousal were very robust and significantly different from placebo. However, levels of arousal were only weakly associated with prospective memory performance despite the presence of a strong drug effect on both parameters. The latter therefore seems to indicate the validity of current observations. It would be advisable to replicate the current findings in a larger sample and, perhaps, with the inclusion of a broader range of memory and attention tests ([@bibr44-0269881118783299]), to further elucidate and differentiate the effects of cocaine.

In summary, the current findings suggest that cocaine administration enhances prospective memory performance, while cannabis tends to impair prospective memory. Prospective memory performance was only weakly associated with measures of attention and arousal, suggesting that cocaine exerts a direct influence on memory processing. Replication studies are needed to examine whether the enhancing effects of cocaine are generalisable to other memory domains, and whether other aspects of attention play a role in these effects.
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